Pharmaceuticals/Chemicals
Estradiol Cypionate
Also called E2 Cyp · Depo-Estradiol
Estradiol cypionate provides estrogen through an injection rather than a daily pill or gel. It is used for low-estrogen symptoms and in feminizing hormone care; the reason for treatment determines the dose and schedule.
Dosage & duration
Distinct menopause and feminizing-care examples; they are not interchangeable.
Depo-Estradiol · menopause label
Product label- Dose
- 1–5 mg per injection
- How often
- Into muscle every 3–4 weeks
- How long
- Periodic reassessment; no fixed cycle
Product-label range for moderate-to-severe menopausal symptoms, not a feminizing schedule.
Sources: 1
UCSF · feminizing-care starting examples
Published example · product-specific- Dose
- 1 mg per week (low initial) or 2 mg per week (initial)
- How often
- Weekly injection; guideline includes IM and under-skin routes
- How long
- Ongoing individualized hormone care
Provider-guideline examples. Response, goals and blood tests guide changes; the label for Depo-Estradiol itself specifies IM use.
Sources: 2
Estradiol injections
Fit the treatment goal
-
Fewer daily steps
An injection replaces a daily application or tablet routine.
-
Keep treatment contexts separate
Menopause prescribing and feminizing hormone care use different treatment plans.
-
Compare at consistent times
Blood-test results change across the injection interval.
Why choose cypionate?
The appeal is an injection routine instead of daily dosing. People comparing cypionate with valerate often want fewer swings or a convenient interval. The best fit also depends on what product is available and how symptoms and blood tests change through the week.
One hormone, different treatment goals
Treating menopausal hot flushes is not the same dosing question as feminizing therapy. The two examples above deliberately preserve their populations and schedules. Taking a dose from one context and an interval from the other creates a regimen neither source describes.
Comparing with valerate
Both release estradiol. Different vial concentrations mean that the same volume may contain different milligrams. Compare the prescribed ester, amount and interval together; do not swap millilitres. A peak in the plot is not a personal target or evidence that higher levels produce faster desired changes.
What deserves follow-up
Review persistent headaches, unexpected bleeding where applicable, and recurring symptoms near an injection date with the clinician. Estrogen-related clot risk and individual medical history matter. If a uterus is present, protecting the womb lining is also part of a systemic-estrogen plan.
Model details: Estradiol Cypionate · relative timing
Compare timing and buildup for this compound. The values are not blood concentrations or a measure of strength.
Shows a relative timing scenario; absolute blood concentrations are not calibrated.
Timing assumptions and sources
Approximate peak timing from Oriowo human IM study; stored 89.65 h terminal rate not established by this source. The retained 89.650000008 h slower timescale is an assumption.
One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.
- Timing half-life used
- 89.65 hours
- Absorption half-life assumed
- 50.73857 hours
- Reference amount for the relative scale
- 1 mg
- The faster rate is inferred to match the 96 h source-scoped peak time; absorption half-life 50.73857155001672 h is a mathematical shape parameter, not separately measured.
- A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
- Widely repeated 337–338 pg/mL at 5 mg is a total-estradiol endpoint; baseline treatment must be established before an exogenous model.
- Arachis-oil study is not proof that every carrier/SC formulation shares kinetics.
- Keep numerical dose serialization; no automatic ester-mass/F multiplier.
- Oriowo et al 1980: three estradiol esters
Single 5 mg IM in 1 m L arachis oil; cypionate peakabout 4 days, valerateabout 2 days; groups 10/9/10 women.
- Depo-Estradiol label
IM ester-in-oil route; prolonged depot absorption; no single-dose absolute PK calibration.
estradiol-cypionate-relative-timing-2026-10 · version 1
Common questions
Is cypionate stronger than valerate?
They are different estradiol esters and products; millilitres and timing are not automatically equivalent. Higher measured peaks are not a measure of better results.
When should blood tests be taken?
Use the timing requested by the treating clinician and record when the last injection occurred. Consistent timing makes results easier to interpret.
Why does estradiol cypionate come up in bodybuilding discussions?
Some PED users discuss adding estradiol after struggling with low-estrogen symptoms or estrogen control. Reported experiences differ and do not establish an effective bodybuilding regimen. The replacement and feminizing-care examples here answer different treatment questions.
Sources Labels, studies and notes behind this guide
Catalog evidence: Other human research. This describes the type of evidence, not a clinical review of every claim.
Summary and fact source checks: 2026-10-07. This records source checking, not medical review of the whole page.
Notes on the quick facts
- Main appeal
- An injection replaces a daily application or tablet routine.
- Important distinction
- Do not treat the menopause label as a gender-affirming regimen.
- Timing matters
- Results change across the injection interval.
- 1. Depo-Estradiol — US product label
Menopausal symptom label: 1–5 mg IM every 3–4 weeks. Separate female hypogonadism indication 1.5–2 mg monthly; neither is a feminizing-therapy schedule.
- 2. UCSF — feminizing hormone therapy guideline
Provider guideline table: injectable estradiol cypionate initial-low 1 mg/week, initial 2 mg/week, maximum 5 mg/week; injectable route IM or SC. Maximum is not a target. Treatment and tests individualized.
- 3. Oriowo et al 1980: three estradiol esters
Single 5 mg IM in 1 m L arachis oil; cypionate peakabout 4 days, valerateabout 2 days; groups 10/9/10 women.
- 4. Depo-Estradiol label
IM ester-in-oil route; prolonged depot absorption; no single-dose absolute PK calibration.
- 5. Depo-Estradiol US prescribing information
Estradiol cypionate in oil for IM use; US menopausal/hypoestrogenism indications.
- 6. Oriowo et al., estradiol ester comparison
Abstract: single 5 mg IM injections in arachis oil; women receiving combined oral contraception; cypionate peaked around day 4, valerate around day 2. Not a modern gender-affirming dosing trial.
- 7. Injectable estradiol dosing in transgender and nonbinary adults, 2025
Original clinical cohort; dose, blood-draw timing and achieved hormone concentrations. Does not establish an interchangeable dose for every ester/route.
Related compounds and examples
Related compounds
Estradiol Topical (EstroGel)
Estradiol gel is used to ease menopausal hot flushes and other low-estrogen symptoms without a pill or injection. The practical choices are the exact pump product, the daily skin routine and whether a separate progestogen is needed.
Estradiol Valerate
Estradiol valerate injections are used for estrogen replacement and feminizing hormone care. Readers usually want a manageable injection routine and fewer swings between doses. The amount, interval and reason for treatment matter more than chasing a high peak.
Progesterone (Oral)
Oral micronized progesterone is often paired with estrogen to protect the womb lining. People also ask about sleep because it can cause drowsiness and has been studied for menopausal symptoms. Those are different reasons for treatment, with different schedules.